In this respect, genetic ablation and pharmacological inhibition of the eATP-P2X7 axis by the broad-spectrum antagonist oxidized ATP (oATP) alleviated dystrophic phenotypes in mouse models of dystrophinopathy and sarcoglycanopathy [18,24,25]. This evidence concerns the gene P2RX7 and sarcoglycanopathy.